On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


The Movie Studio Inc. (MVES) Gains Ground as Audiences Cut Cable, Opting for Video on Demand

  • From 2018 to 2019, the number of people who cut cable more than tripled
  • Video on demand is seeing, predicting continued growth
  • Company offering unique options such as ‘moviesodes’ and audition opportunities to app users

Amid the economic turmoil of today, one sector is consistently showing growth during the worldwide pandemic of COVID-19. Already valued at $56.55 billion in 2019, the video on demand (VoD) industry is predicted to reach $120.91 billion by 2025 (http://ibn.fm/Om9N8). With more people looking to social distance and stay at home, the industry continues to see a boom. These same customers are turning to smart television and apps that give them the freedom and financial flexibility to watch what they want when. This exodus is good news for companies such as The Movie Studio Inc. (OTC: MVES), whose business model includes subscription and advertiser video on demand (SVoD/AVoD) along with over the top (OTT) services.

As early as March 25, 2020, an article in Forbes predicted that COVID-19 would create a 50% to 70% surge of internet use, with streaming jumping up by 12% (http://ibn.fm/5mLSp). With the combination of smart television, apps, and more than 12,000 people cutting their cable cords every day, VoD is strategically positioned to explode, with one source noting that 1.6 million customers opted out of cable services in 2018, and, in 2019, that number more than tripled, passing 4.9 million (http://ibn.fm/Mz0Xy).

MVES is disrupting traditional media-content delivery systems with the intention to create a direct-server access platform of its own content for worldwide distribution. The company acquires, develops, produces and distributes independent motion pictures for worldwide consumption and is strategically aligned with distribution brands such as Amazon Prime, Showtime, MGM and others.

The Movie Studio App is available in the Apple App Store and the Google Play Store. The company releases movies in chapter format, which are called ‘moviesodes’. The Movie Studio App also offers a “audition to submission” feature, allowing users to have a role in an upcoming movie.

Based in South Florida, MVES is in preproduction for two films: Cause & Effect is about the seedy underbelly of Miami’s nightlife, while Pegasus, scheduled to be the company’s signature film, is about a young girl and a horse. MVES is currently the only major independent studio located in South Florida.

In addition to providing its own titles, MVES entered into a licensing agreement in April 2020 with FILMHUB, an online marketplace for film creators and streaming services. This allows for the viewing of FILMHUB’s catalog on The Movie Studio App in addition to MVES independent productions. This agreement also makes MVES titles available to FILMHUB and its associated OTT partners, providing a larger audience and fan base (http://ibn.fm/VOBCD).

Previously known as Destination Television Inc., The Movie Studio is strategically positioned to capitalize on the quickly changing viewing habits of audiences worldwide.

For more information, visit the company’s website at www.TheMovieStudio.com

NOTE TO INVESTORS: The latest news and updates relating to MVES are available in the company’s newsroom at http://ibn.fm/MVES

From Our Blog

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Mines Investment-building Opportunity for Brain Tumor-Targeting Drug Candidate at Annual Conference

September 23, 2020

CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system The company will be applying for approval to launch Phase II trials in the first quarter of 2021 for its leading drug candidate, Berubicin, which targets glioblastoma multiforme (“GBM”) brain cancer CNS Pharmaceuticals CEO addressed […]

Rotate your device 90° to view site.